<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820311</url>
  </required_header>
  <id_info>
    <org_study_id>0136</org_study_id>
    <nct_id>NCT02820311</nct_id>
  </id_info>
  <brief_title>Thorough QT (TQT) Study of TD-4208 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo- and Positiveâˆ’Controlled, 4-Period Crossover Thorough QT Study to Evaluate the Effect of a Single Dose of TD-4208 on Cardiac Repolarization in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma R &amp; D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if TD-4208, an investigational drug being developed
      to treat people with chronic obstructive pulmonary disease (COPD), has any effect on the
      electrical activity of the heart.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change-from-baseline in corrected QT</measure>
    <time_frame>Predose to 24 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration Cmax</measure>
    <time_frame>Predose to 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Predose to 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cardiac Repolarization in Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>TD-4208 175 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-4208 700 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for TD-4208</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>open-label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-4208 175 mcg</intervention_name>
    <description>via nebulizer</description>
    <arm_group_label>TD-4208 175 mcg</arm_group_label>
    <other_name>revefenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-4208 700 mcg</intervention_name>
    <description>via nebulizer</description>
    <arm_group_label>TD-4208 700 mcg</arm_group_label>
    <other_name>revefenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for TD-4208</intervention_name>
    <description>via nebulizer</description>
    <arm_group_label>Placebo for TD-4208</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400 mg</intervention_name>
    <description>oral</description>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a body mass index (BMI) of 19 to 32 kg/m2, inclusive, and weight of at
             least 55 kg.

          -  Subject is able to communicate well with the investigator and to comply with the study
             procedures, requirements, and restrictions.

        Exclusion Criteria:

          -  Subject has a prior history of myocardial infarction, acute coronary syndrome,
             cerebrovascular accident, transient ischemic attack, ventricular tachycardia, atrial
             fibrillation, personal or known family history of congenital long QT syndrome or known
             family history of sudden death with unknown cause, a pacemaker or implantable
             cardioverter defibrillator, cardiac or cerebral stent placement or angioplasty, or
             clinically significant valvular heart disease.

          -  Subject has evidence or history of clinically significant allergic (except for
             untreated, asymptomatic, seasonal allergies at time of dosing), hematologic,
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or
             neurological disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Bourdet</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thorough QT (TQT)</keyword>
  <keyword>cardiac safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

